Customized medication is another mantra developing in human services. Tackling every individual's clinical, hereditary, genomic, and natural data drives the idea. The thought is basic. We can amplify a patient's odds of a superior result in the event that we base medicines on what we know. Be that as it may, isn't this from numerous points of view the manner in which it's constantly been? Isn't this to a limited extent the reason for that bygone era house call? To perceive how a malady or condition is being thought about in the home condition? Clinicians have since a long time ago utilized customized medication, without plain utilization of single nucleotide polymorphisms, however unquestionably not thoroughly drained of hereditary data. Obviously, doctors of the past didn't have quality chips, however they had family ancestries regularly illuminating their choices. Today as we raise the desires for focused treatments to break us liberated from the algorithmic medicines frequently followed by hit and miss draws near, there is a recharged intensity for customized medication. How would we arrive and how does the normal clinician or analyst comprehend the expanding exhibit of data, talking heads, and most recent publicity of subgroup benefits? A key viewpoint is to confide in your preparation, your experience, and your impulses, combined with a couple of rehashed dosages of biostatistics.The objective of customized medication is to improve treatment results and decrease unfriendly occasions that issue to both the clinician and patient. As indicated by the Personalized Medicine Coalition (PMC) in Washington, there were 13 instances of customized medication analytic biomarkers and drugs in 2006, and 72, more than multiple times more, in 2011. The concentration and restricted, however amazing achievement of customized medication has been in malignant growth and few incessant ailments. Explicit results in malignant growth give guarantee to comparative advances of customized medication in nervous system science. A few models are illustrated. Herceptin (trastuzumab) utilized in bosom disease is coordinated to the 30% of bosom malignancies with an overexpression of HER-2 protein, which react to Herceptin. Gleevec (Imatinib mesylate) is utilized to treat ceaseless myeloid leukemia, which has expanded future from 5% to 95% at 5 years. Zelboraf (Vemurafenib) is utilized to treat melanoma, where the late-stage forecast has been bleak, yet 60% of patients have a deformity in their DNA, and this medication benefits those with the V600E imperfection.